We are live on ! Find out more
ANTH

Anthera Pharmaceuticals, Inc.
ANTH

Delisted

ANTH was delisted on the 27th of June, 2018.

Back to rankings

35 hedge funds and large institutions have $3.21M invested in Anthera Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

13% less funds holding

Funds holding: 40 → 35 (-5)

33% less capital invested

Capital invested by funds: $4.81M → $3.21M (-$1.6M)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
35
Holders Change
-5
Holders Change %
-12.5%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
9
Closed
11
Calls
$427K
Puts
–
Net Calls
+$427K
Net Calls Change
-$158K

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$70.1K
2
Neuberger Berman Group
Neuberger Berman Group
New York
+$48.3K
3
WS
Wedbush Securities
California
+$45.2K
4
UBS Group
UBS Group
Switzerland
+$32.3K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$26.6K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$768K
2
RSCM
Rock Springs Capital Management
Maryland
-$82.5K
3
ECM
Element Capital Management
New York
-$70K
4
Goldman Sachs
Goldman Sachs
New York
-$69K
5
PP
Paloma Partners
Connecticut
-$60K
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
26
Ladenburg Thalmann Financial Services
Florida
$2K – – –
RE
27
RBC Europe
United Kingdom
$1.26K +$1.24K +875 New
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$1K – – –
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$9 – – –
ECM
30
Element Capital Management
New York
– -$70K -43,107 Closed
Goldman Sachs
31
Goldman Sachs
New York
– -$69K -42,692 Closed
PP
32
Paloma Partners
Connecticut
– -$60K -37,200 Closed
LP
33
LMR Partners
United Kingdom
– -$47K -28,743 Closed
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
– -$37.5K -26,428 Closed
RPAM
35
Rhenman & Partners Asset Management
Sweden
– -$41K -25,000 Closed
PAM
36
Panagora Asset Management
Massachusetts
– -$16K -9,791 Closed
DADC
37
D.A. Davidson & Co
Montana
– -$12K -8,016 Closed
TRCT
38
Tower Research Capital (TRC)
New York
– -$977 -688 -80%
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
– +$4 +3 +2%
Barclays
40
Barclays
United Kingdom
– +$68 +48 +1,600%
FMA
41
FNY Managed Accounts
New York
– +$284 +200 New
1
2

ANTH Hedge Fund Activity: Q3 2017 in Review

35 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q3 2017, worth a combined $3.21M — down 33% from $4.81M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ANTH and 7 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 10 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $70.1K. The largest seller was Sabby Management, cutting an estimated $768K.

  • 35 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q3 2017, down from 40 in Q2 2017.
  • Funds reported $3.21M of Anthera Pharmaceuticals, Inc. stock for Q3 2017, down 33% quarter-over-quarter.
  • 7 funds opened new Anthera Pharmaceuticals, Inc. positions in Q3 2017 and 11 closed out, a net change of -4 holders.
  • The largest Anthera Pharmaceuticals, Inc. buyer in Q3 2017 was Two Sigma Securities, an estimated $70.1K added.
  • The largest Anthera Pharmaceuticals, Inc. seller in Q3 2017 was Sabby Management, an estimated $768K sold.

Based on aggregated 13F filings for Q3 2017.